Shareholders of Harris & Harris Group may be interested to read an article by Arlene Weintraub on Xconomy.com entitled, "Mersana Adds $4M For Next-Generation "Armed" Cancer Drugs ." The article may be accessed at http://www.xconomy.com/boston/2012/05/01/mersana-adds-4m-for-next-generation-armed-cancer-drugs/.
Harris & Harris Group is an investor in privately held Mersana Therapeutics, Inc.
Harris & Harris Group is an early-stage, active investor in transformative nanotechnology companies. Detailed information about Harris & Harris Group and its holdings can be found on its website at ir.hhvc.com.
This news release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this news release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites ir.hhvc.com and www.xconomy.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this news release. Harris & Harris Group is not responsible for the contents of third party websites.